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Abstract—The study's objective was to describe the effect of using high doses of N-acetylcysteine on severe COVID-19 patients. N-
acetyl cysteine, known as a mucolytic agent, in high doses (>1200 mg/day) is also known as glutathione boosting treatment, that may 
reduce proinflammatory cytokine so it may beneficial reduce the risk of severity. This study was an observational descriptive,  evaluated 
from the length of stay of all patients with severe COVID-19 (clinical signs of pneumonia plus severe respiratory distress) and by 
monitoring the drug use data, laboratory data, and clinical data at Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya. The data 
was collected retrospectively from patients' Health Medical Records who got high dose N-acetylcysteine in October 2020 – February 
2021, with standard therapy: antivirus (Remdesivir), antibiotics, vitamins, symptomatic and comorbid therapy, anticoagulant, and 
corticosteroids (Dexamethasone) as inclusion criteria, then described descriptively. The observation result confirmed that the use of a 
high dose of N-acetylcysteine (NAC) [1 x 1200 – 5000 mg] po/iv had effective and beneficial results as seen from the patients' length of 
stay, which was 12 days for patients without comorbid and 14 days for patients with comorbid like diabetes and/or hypertension. The 
use of high dose NAC showed improvement in the patients' clinical condition that is evaluated from improved oxygen saturation by 37%. 
In addition, the laboratory results are shown an improvement in thorax X-ray by 69% and inflammatory markers like CRP and d-dimer by 
100%. Further research that uses a prospective method is needed to get a better result on the use of high-dose NAC in patients with 
severe COVID-19. 
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Abstrak—Tujuan dari penelitian ini adalah untuk mendeskripsikan efek penggunaan N-acetylcysteine dalam dosis tinggi 
(>1200mg/hari) pada pasien COVID-19 yang parah (dengan gejala klinis pneumonia disertai dengan distress pernafasan berat) , dinilai 
dari lama rawat dan dengan pemantauan data penggunaan obat, data laboratorium, dan data klinis di RS Bhayangkara H.S Samsoeri 
Mertojoso Surabaya. Data dikumpulkan secara retrospektif dari Rekam Medis Kesehatan pasien yang mendapat N-asetilsistein dosis 
tinggi pada Oktober 2020 – Februari 2021, dengan terapi standar: antivirus (Remdesivir), antibiotik, vitamin, terapi simtomatik dan 
komorbiditas, antikoagulan, dan kortikosteroid (Dexametason) sebagai kriteria inklusi, kemudian dideskripsikan secara deskriptif. Hasil 
observasi menegaskan bahwa penggunaan N-acetylcystein (NAC) dosis tinggi [1 x 1200 – 5000 mg] po/iv memiliki hasil yang efektif dan 
memberi benefit dilihat dari lama rawat pasien yaitu 12 hari untuk pasien tanpa penyakit penyerta dan 14 hari untuk pasien dengan 
penyakit penyerta seperti diabetes dan/atau hipertensi. Penggunaan NAC dosis tinggi menunjukkan perbaikan kondisi klinis pasien yang 
dinilai dari peningkatan saturasi oksigen sebesar 37%. Selain itu, hasil laboratorium menunjukkan peningkatan seperti pada rontgen 
toraks sebesar 69%, dan penanda inflamasi seperti CRP dan d-dimer sebesar 100%. Diperlukan penelitian lebih lanjut yang 
menggunakan metode prospektif untuk mendapatkan hasil yang lebih baik pada penggunaan NAC dosis tinggi pada pasien COVID-19 
berat. 
 
Kata kunci: dosis tinggi, pasien Covid-19 parah,  n-asetilsistein 
 
INTRODUCTION 
Coronavirus Disease (COVID-19) is caused by the Severe Acute Respiratory Syndrome 
Coronavirus-2 (Levani et al., 2021; Organization, 2020; Susilo et al., 2020).  This disease was first 
reported on December 31, 2019, in Wuhan, China, as pneumonia of unknown cause (Liskova et al., 
2021; RI, 2020). Then it quickly spread throughout the world. WHO, on March 11, 2020, declared 
COVID-19 a pandemic (Dos & Wagner, 2020) 
The increase in the number of cases is relatively fast and has spread to various countries 
worldwide. Globally, as of early December 2020, there were 65,257,767 million confirmed cases 
and 1.5 million deaths, with the highest number of cases in America, Europe, and Southeast Asia. 
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(Khaira, 2010; Moradi and Hadi, 2021; Organization, 2020). In Southeast Asia, there were 
11,023,450 cases with a death toll of 167,782. Indonesia as the largest contributor to cases, since 
January 3, 2020, confirmed 563,680 cases of COVID-19 with 17,479 deaths. (Khaira, 2010; Moradi 
& Hadi, 2021; Organization, 2020). 
COVID-19 is grouped based on the severity of cases into asymptomatic, mild, moderate, 
severe, and critical cases (Alfhad et al., 2020; Lai et al., 2020; Suryadinata, 2018). The criteria for 
mild COVID-19 are patients with symptoms without evidence of viral pneumonia or hypoxia 
(Roorda, 2016). Common symptoms include fever, cough, fatigue, shortness of breath, muscle 
aches. In addition, patients also experience sore throat, nasal congestion, headache, diarrhea, 
nausea and vomiting, loss of smell (anosmia), or loss of taste (ageusia) (Davies, 2002; Djalante et 
al., 2020). In moderate grade patients, the patient showed clinical signs of pneumonia (fever, 
cough, shortness of breath, rapid breathing) but no signs of severe pneumonia, including oxygen 
saturation (SpO2),>93%. The criteria for rapid breathing at the age of <2 months is >60x/minute, 
age 2-11 months is >50x/minute, age 1-5 years is >40x/minute, age >5 years is >30x/minute. In 
severe cases, patients show clinical signs of pneumonia plus one respiratory rate >30/min, severe 
respiratory distress (rapid breathing, grunting, very heavy chest indrawing), or SpO2 <93% on 
room air (central cyanosis). Critical patients are those with ARDS, sepsis, and septic shock (Burhan 
et al., 2018; Tian et al., 2020; Zhou et al., 2020). 
Management for COVID-19 patients is given non-pharmacological and pharmacological 
therapy. Pharmacological therapy in asymptomatic COVID-19 patients includes administering 
vitamin C, vitamin D, and drugs with antioxidant properties (Rusdi, 2021; Sujana & Maulida, 2021; 
Vivianni & Farhanah, 2016). In mild grade patients, patients are given multivitamins like 
asymptomatic patients and are also given antibiotics (Azithromycin), antivirals (Oseltamivir, 
Favipirapir). In moderate-grade patients, patients are given multivitamins, antibiotics 
(Azithromycin or Levofloxacin), antivirals (Favipirapir or Remdesivir), Low Molecular Weight 
Heparin (LMWH) / Unfractionated Heparin (UFH) anticoagulants. In severe or critically ill patients, 
oxygen therapy is given if the oxygen saturation SpO2 is <93%, then multivitamins, antibiotics 
(Azithromycin or Levofloxacin), antivirals (Favipiravir or Remdesivir), LMWH/UFH anticoagulants, 
dexamethasone are given. Other therapies or additional measures that can be given to COVID-19 
patients are Anti-IL-6 (Tocilizumab), Anti IL-1 (anakinra), stem cells, intravenous immunoglobulin 
(IVIg), convalescent plasma therapy, vaccination, N-acetylcysteine, colchicine, spironolactone, 
bronchoscopy, and therapeutic plasma exchange (TPE) (Burhan et al., 2018; Mazzaro et al., 1993; 
Sari et al., 2017). 
In this study, we focused on N-acetylcysteine (NAC) because most COVID-19 patients had 
severe pneumonia with excess mucus in the respiratory tract (Ochs et al., 2012; Sari et al., 2015; 
Yuliana, 2020). The usual dose of NAC in pneumonia is (3x200 mg) po, used as a mucolytic agent. 
Still, NAC also has antioxidant and anti-inflammatory effects when used in high doses (600 – 2400 
mg/day) po, iv, inhalation (De Flora et al., 2020; Djalante et al., 2020). Based on the COVID-19 
Management Manual by the Indonesian Lung Doctors Association (PDPI), the dose of NAC used is 
above or equal to 1200 mg per day orally or intravenously with 2-3 times, especially for severe 
COVID-19. N-Acetylcysteine is used at Bhayangkara Hospital Surabaya based on the COVID-19 
Management Manual by PDPI. It is also supported by evidence-based medicine research journals, 
which in practice at the hospital is used N-Acetylcysteine at a dose of 5 grams per day 
intravenously given in 500 ml PZ infusion over 6-8 hours. In addition, in the COVID-19 Hospital 
Clinical Practice Guidebook, Dr. Soetomo Surabaya, high dose of N-Acetylcysteine (NAC) 5 grams 
per day given in 500 ml NaCl 0.9% or Dextrose 5% intravenous drip 4 hours (Damayanti & Ryusuke, 
2017; Sari et al., 2015, 2017). 
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SARS-CoV-2 infection is associated with an imbalance of oxidants and antioxidants, 
resulting in inflammation and tissue damage (Damayanti and Ryusuke, 2017). Glutathione is an 
antioxidant widely found in the body and plays a role in protecting cells from oxidative stress 
(Burhan et al., 2018). Giving NAC as a "glutathione-boosting treatment" can reduce pro-
inflammatory cytokines to reduce the risk of the severity of COVID-19 caused by cytokine storms 
in the body (Medicine, 2020; Nasi et al., 2020; Spearow & Copeland, 2020). 
Liu (Liu, 2020) treated a 64-year-old male COVID-19 patient who experienced respiratory 
failure on the thirteenth day after hospital admission, despite being given an antibiotic, antiviral, 
and respiratory support therapy. Simultaneously with the therapy that has been carried out, the 
patient is given a bronchoscopy rinse method therapy with high doses of inhaled NAC solution (10-
15 g) to clear the airways given for 11 days at one or two-day intervals, 10 to 15 g of NAC solution 
is infused into each patient. Bronchus alternately left, and right, the solution is maintained for two 
to three minutes, and then cleared by sucking using negative pressure. This therapy provides 
significant results in critically ill patients. The patient was discharged from the hospital after 26 
days of mechanical ventilation and 46 days of hospitalization.  
Ibrahim et al. (2020)  also conducted a study of administering NAC to 9 patients with 
severe COVID-19, who depended on a respirator, aged 38-71 years. In nine COVID-19 patients, 
NAC was given with details of one patient (2 x 10 g) iv and eight patients (2 x 600 mg) iv. NAC 
administration significantly reduced inflammatory mediators such as C-reactive Protein (CRP) (the 
mean value of CRP levels before NAC was 160±97 mg/dL and after NAC therapy was 31±24 mg/dL) 
and the mean ferritin before administration. NAC therapy was 3630 ng/mL, and after therapy, it 
was 1543 ng/mL. In addition, it also improves lung function. Then out of ten COVID-19 patients, 
eight patients were discharged from the hospital, and two patients showed improvement in their 
condition even though they had not been discharged from the hospital. 
Research from Sari et al. (Sari et al., 2015) related the effectiveness of high doses of N-
Acetylcysteine in severe COVID-19 patients with oxygen saturation less than 94% or an average 
respiratory rate higher than 24 breaths per minute. Patients were randomly assigned to NAC 21 g 
for 20 hours, or 5% dextrose to the placebo group. The results were observed from the need for 
mechanical ventilation, mortality rate, number of ICU admissions, length of stay in the ICU, and 
length of hospital stay. They showed no significant difference between the two groups. 
Based on the description above, it is necessary to research the use of high doses of N-
acetylcysteine (NAC) in COVID-19 patients to confirm whether or not the therapy has an impact. 
 
METODE  
This observational research was conducted at Bhayangkara Hospitals. Samsoeri Mertojoso 
Surabaya from February-March 2021. The study population was all COVID-19 patients at 
Bhayangkara H.S. Hospitals. Samsoeri Mertojoso Surabaya for the period October 2020 to 
February 2021. All of the severe COVID-19 patients  (diagnosed by pulmonologist based on 
Management Guideline by PDPI 2020) and receiving high-dose N-acetylcysteine therapy (greater 
than or equal 1200mg by any route) that hospitalized at Bhayangkara Hospital Samsoeri  
Mertojoso Surabaya for the period October 2020 to February 2021 were included as a sample. The 
research sample was selected with two criteria. First, the patient was diagnosed with severe 
COVID-19 (pneumonia, with respiratory distress, respiratory rate >30x/mnt, saturation <93%, and 
ratio PaO2/FiO2<30) and received high-dose N-acetylcysteine therapy  (≥ 1200 mg/day by oral or 
intravenous ). Second, the patient received the same standard COVID-19 protocol therapy 
according to the COVID-19 Guideline Management Manual by PDPI 2020. After tracing the medical 
record data of COVID-19 patients during the period October 2020 - February 2021, from 156 
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patients with severe COVID-19 hospitalized, it was found that patients who met the inclusion 
criteria were 60 people. 
The research material is Health Medical Record data of patients diagnosed with severe 
COVID-19 at Bhayangkara H.S. Hospital. Samsoeri Mertojoso Surabaya and based on the daily 
observation sheets on patients in October 2020 - December 2021. The instruments of this research 
are Data Collection Sheets, master tables, clinical datasheets, and laboratory data of the patients. 
Data were obtained from medical records of severe COVID-19 patients who received high-dose N-
acetylcysteine therapy at Bhayangkara H.S. Hospital. Samsoeri Mertojoso Surabaya.  
The collected data were analyzed quantitatively in percentage to describe: (1) The patient 
demographics (gender and age), duration of administration of N-Acetylcysteine, and length of 
patient care. Data is presented in the form of tables, diagrams, and descriptions; (2) the 
identification of drug dosing, frequency, duration of administration, and time to start high-dose N-
acetylcysteine therapy in COVID-19 patients; (3) The binding of laboratory data such as 
inflammatory mediators (CRP, ferritin, d-dimer, fibrinogen), RT-PCR, complete blood count, chest 
X-ray; clinical data such as oxygen saturation; with the results of therapy (outcomes) in patients 
(whether the patient is still experiencing symptoms such as shortness of breath, cough) which is 
presented in the form of tables and descriptions; and (4) The side effects of N-Acetylcysteine in 
patients and drug interactions with other drugs. 
 The outcome assessment was clinical recovery with laboratory and chest x-ray 
parameters. Inflammatory markers evaluated were CRP, d-dimer, IL-6, and/or fibrinogen  ( not all 
of these must be included, because not all of these markers were monitored, or so that only one 
or two inflammatory markers could be shown before and after therapy). In addition, a serial chest 
x-ray was performed to assess clinical improvement. 
 
FINDING AND DISCUSSION  
Patient Demographics 
In research from Medicine (Medicine, 2020),  More cases of COVID-19 are in the male sex. 
In this study, male patients were 72% (n=43), and female patients were 28% (n=17), as listed in 
Table V.1. From Bwire's (2020) study, looking at genetics, the analysis shows that men have higher 
ACE-2 protein expression than women. Then, immunologically, as explained by Elgendy and 
Pepine (2020), the differences in immunity between men and women are caused by sex hormones 
and the X chromosome, as shown by experiments with mice when female mice were subjected to 
estrogen receptor inhibition and mortality due to SARS-CoV infection increased, so it was 
concluded that the estrogen receptor has a role in blocking some viral infections. In terms of 
habits, men tend to have smoking habits and alcohol consumption (Elgendy and Pepine, 2020). 
This can increase oxidative stress and cause reduced antioxidant protection, increased oxidative 
stress due to several mechanisms, namely direct damage due to radical species and inflammatory 
responses (Kamceva et al., 2016).  
The above results reflect the agreement with the study results by Zheng et al. (2020), 
which showed that men over 65 years of age and smoking habits had a greater risk of experiencing 
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Table 1 
Number and Percentage of Age Distribution of Severe COVID-19 Patients Hospitalized 
 
Age Range Number of Patients 
21 – 30 3 (5%) 
31 – 40 6 (10%) 
41 – 50 15 (25%) 
51 – 60 27 (45%) 
61 – 70 7 (11%) 
71 – 80 1 (2%) 
81 – 90 1 (2%) 
 
From Table 1, the highest age of patients with severe COVID-19 hospitalized was in the 51-
60 age range, which is 45% (n=27). It is increasingly supported by the results of research from 
Robert (2020), which also states that the older adult group is easier to experience severe illness 
due to COVID-19 with an increased risk at the age above 50-60 years because, at this age, the 
immune system is less reactive (immune senescence). Symptoms of COVID-19 are non-specific, 
such as fever (which is the immune system's response to an infection), so these symptoms may be 
weaker or absent in old age, leading to delayed treatment. 
 
Table 2  
Number and Percentage of Comorbid Distribution in COVID-19 Patients 
 
Comorbid Number of Patients 
With Comorbid 40 (67%) 
No Comorbid 20 (33%) 
 
Table 3 
Comorbidities in Severe COVID-19 Patients 
 
Comorbid (Comorbid Disease) Number of Patients * 
Diabetes mellitus 26 (65%) 
Hypertension 23 (58%) 
Heart disease 2 (5%) 
Dyslipidemia 1 (3%) 
*Note: Patients can experience more than 1 type of comorbidity 
 
Table 2 shows the presence or absence of comorbidities in severe COVID-19 patients. It is 
known that 67% (n=40) had comorbid and 33% without comorbidity (n=20). Of the 40 patients 
who had comorbidities (comorbidities), the most common comorbidities experienced were 
diabetes mellitus, with 26 patients listed in Table 3. This is following the research that states that 
comorbid conditions such as hypertension, diabetes, cardiovascular disease also increase the risk 
of COVID-19 (Zheng et al., 2020). COVID-19 patients with comorbid diabetes mellitus show a 
dysregulation of glucose metabolism in the body, an increase in inflammation, and a decrease in 
the immune system. Conditions like this can cause oxidative stress in the body and increase 
cytokine production, allowing organ damage (Lim et al., 2020). 
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Table 4 shows the initial symptoms experienced by severe COVID-19 patients, and it was 
found that cough was the most common symptom experienced by patients, which was 85% (n=51 
patients). From the results of the diagnosis, it was found that 95% (n=57 patients) had bilateral 
pneumonia, ARDS (Acute Respiratory Distress Syndrome) was 17% (n=10 patients), and bronchitis 
was 3% (n=2 patients). This is following the classification of COVID-19 described in the COVID-19 
Management Manual by PDPI  2020, namely severe COVID-19 in adult patients showing clinical 
signs of pneumonia (fever, cough, shortness of breath, rapid breathing) plus one of the signs of 
respiratory frequency. >30x/minute, severe respiratory distress, or SpO2 < 93% in room air; and is 
critical if you have ARDS, sepsis, and septic shock. 
 
Table 4 
Symptoms Experienced by Severe COVID-19 Patients 
 
Symptom Number of Patients * 
Cough 51 (85%) 
Faver 39 (65%) 
Dyspnea 32 (53%) 
Nauseous vomit 21 (35%) 
Malaise  
Flu like symptoms 
13 (22%) 
12 (20%) 
          Anosmia 7 (12%) 
Headache 4 (7%) 
Diarrhea 4 (7%) 
Heartburn 2 (3%) 




Chest pain 1 (2%) 
Stomach pain 1 (2%) 
  
 
High-dose NAC Usage Profile 
This study found that the most widely used was iv NAC (1x5000 mg) in 48% of patients 
(n=29). The route of using NAC that patients with severe COVID-19 widely use is the intravenous 
route by 65% (n=46). Administration by the oral route was 35% (n=24), with a note that one 
patient could receive more than one route of administration. As many as 23% (n=14 patients) 
received a switch dose, and this was due to the smaller dose being used for the maintenance dose. 
Changing the route of use from intravenous to oral is also done because the use of other drugs by 
the intravenous route is no longer given. Details of the use of NAC can be seen in Table 5. The 
study results are following the literature, namely the dose of NAC is given 5 grams per day in 500 
ml NaCl 0.9% or Dextrose 5% intravenous drip 4 hours for three days. On the fourth day followed 
by maintenance 600 mg every 8-13 hours orally or by intravenous drip 2 hours in 100 ml of 0.9% 
NaCl or 5% Dextrose. As in the NAC literature, it is given until there is clinical improvement, 
improvement of chest X-ray, reduction of CRP (<10 mg/dL), or improvement of hyper 
inflammation (Suprabawati, 2020). 
In patients without comorbidities, the use of NAC dose (1x1800 mg) iv provided the 
shortest treatment period of 11 days. Doses (1x1200 mg) iv and (3x400 mg) po indicate the 
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treatment period for 12 days. The length of treatment is calculated from MRS (hospital admission) 
to KRS (hospital discharge) in a state of recovery or improvement, not those who are forced to go 
home or die. 
In patients with comorbid diabetes mellitus, NAC's most widely used dose is (1x5000 mg) 
iv. This dose has an average length of treatment of 16 days, and this is because there are patients 
who have a worse clinical condition (as inpatient number 31 in the Master Table) than four 
patients who were given a dose of NAC (3x400 mg) po. 
 
Table 5 
Dosage and Frequency of High-Dose NAC Received by Severe COVID-19 Patients 
 
Medicine name Dosage and Frequency Number of 
patients 
NAC 
(1 x 5000 mg)  iv 29 (48%) 
(1 x 2500 mg) iv 1 (2%) 
(1 x 1800 mg) iv 1  (2%) 
(1 x 1200 mg) iv 2 (3%) 
(3 x 400 mg) po 13 (22%) 
(1 x 5000 mg) iv  (1 x 1200 mg) iv 1  (2%) 
(1 x 5000 mg) iv  (3 x 400 mg) po 5 (8%) 
(3 x 400 mg) po  (1 x 5000 mg) iv 2 (3%) 
(1 x 1200 mg) iv  (1 x 5000 mg) iv 1 (2%) 
(1 x 1800 mg) iv  (1 x 5000 mg) iv  (1 x 1800 mg) iv 1 (2%) 
(3 x 400 mg) po  (3 x 600 mg) po 1 (2%) 
(3 x 400 mg) po  (1x 5000 mg) iv  (3 x 400 mg) po 1 (2%) 
(2 x 2500 mg) iv  (1 x 2500 mg) iv  (3 x 400 mg) po 1  (2%) 
(1 x 5000 mg) iv  (3 x 400 mg) po  (1 x 5000 mg) iv + (3 
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Table 6 






Patients with  




















of px  
avLOS 
Number 
of px  
avLOS 
Number 
of px  
avLOS 
Number 
of px  
avLOS 
Number 
of px  
avLOS 
(1 x 5000 mg)  iv 11 px 13 days 8 px 16 days 3 px 12 days 1 px 12 days 5 px 11 days 1 px 12days 
(1 x 2500 mg) iv 0 0 1 px 12 days 0 0 0 0 0 0 0 0 
(1 x 1800 mg) iv 1 px 11 days 0 0 0 0 0 0 0 0 0 0 
(1 x 1200 mg) iv 1 px 12 days 0 0 0 0 1 pasien 14 days 0 0 0 0 
(3 x 400 mg) po 4 px 12 days 4 px 10 days 3 px 10 days 0 0 2 px 13 days 0 0 
(1 x 5000 mg) iv  (1 x 1200 mg) 
iv 
0 0 0 0 0 0 0 0 1px 18 days 0 0 
(1 x 5000 mg) iv  (3 x 400 mg) 
po 
2 px 12 days 1 px 20 days 1 px 9 days 0 0 1 px 10days 0 0 
(3 x 400 mg) po  (1 x 5000 mg) 
iv 
0 0 0 0 1 px 15 days 0 0 0 0 0 0 
(1 x 1200 mg) iv  (1 x 5000 mg) 
iv 
1 px 14 days 0 0 1 px 16 days 0 0 0 0 0 0 
(1 x 1800 mg) iv  (1 x 5000 mg) 
iv  (1 x 1800 mg) iv 
0 0 0 0 0 0 0 0 1 px 24days 0 0 
(3 x 400 mg) po  (3 x 600 mg) po 0 0 0 0 0 0 0 0 1 px 17days 0 0 
(3 x 400 mg) po  (1x 5000 mg) iv 
 (3 x 400 mg) po 
0 0 0 0 1 px 13 days 0 0 0 0 0 0 
 
 
In patients with comorbid hypertension, the number of patients given NAC dose (1x5000 
mg) iv was the same as the dose (3x400 mg) po, namely three patients. In addition, the switch 
dose is also widely used in comorbid hypertension, which is five patients. The switch dose from 
doses (1x5000 mg) iv to (3x400 mg) po indicates the shortest treatment period, which is nine days. 
In patients with cardiac comorbidities, administering a dose of NAC (1x5000 mg) iv showed a 
shorter treatment period of 12 days. 
  Then the dose (3x400 mg) po, which is 14 days. Patients with comorbid dyslipidemia were 
also given a NAC (1x5000 mg) iv dose with a 12-day treatment period. 
Patients with comorbid diabetes mellitus and hypertension were given the most doses of 
NAC (1x5000 mg), indicating an average length of stay of 11 days. A total of one patient who was 
given a switch dose (1x5000 mg) iv to (3x400 mg) po had a treatment duration of 10 days. One of 
the cases of comorbid diabetes mellitus and hypertension patients with a treatment period of 24 
days of treatment is Mr. DH (patient number 8 in the Parent Table) aged 46 years who were given 
a dose of NAC (1 x 1800 mg) iv (1 x 5000 mg) iv. The patient came with complaints of cough, 
shortness of breath, and fever. The patient has comorbid hypertension and diabetes mellitus, 
history of drug use is Amlodipine (1x5 mg) po and Glucophage (1x500 mg) po. The patient was 
diagnosed with COVID-19, bilateral pneumonia, diabetes mellitus, hypertensive heart disease 
(HHD), and ARDS. NAC (1 x 1800 mg) iv reconstituted in 100 ccs of PZ infusion solution was started 
on the second day of treatment until the eighth day, then its use was replaced with NAC (1 x 5000 
mg) iv on days 9 to 13. Then from the 14th to the 16th day, NAC (1 x1800 mg) is given again. From 
the 17th day until the KRS day (24th day), high doses of NAC were not given anymore. Laboratory 
results in quantitative CRP value on the second day was 51.5 mg/L (reference value < 5.0 mg/L), 
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then increased on the third day to 64.9 mg/L and decreased on the fifth day to 16.6 mg/L, there 
was no further follow-up for quantitative CRP.  
The d-dimer value on the second day of examination showed a value of 118 ng/mL 
(reference value <500 ng/mL) which then on the third day of the d-dimer examination showed a 
value of 166 ng/mL (normal). Then, on the fourth day, it showed a value of 117 ng /mL (normal). 
On day six, the d-dimer rose to 400 ng/mL (normal). Finally, on day 22 it rose to 499 ng/mL (high). 
On Mr. DH, blood gas analysis was performed on the first day, and the measured pO2 value 
showed 137 mmHg (high) and pCO2 was 37 (normal). On the second day, pO2 dropped to 23 
mmHg (low), and pCO2 dropped to 31.3 mmHg (low). On the third day, pO2 rose to 77 mmHg 
(low), which was still below normal, and pCO2 rose to 28.1 (low) mmHg, which was still below 
normal. On the fourth day, pO2 rose to 116 mmHg (high) but pCO2 slightly decreased to 27.1 
mmHg (low). On the fifth day, pO2 and pCO2 showed normal values, namely 92 mmHg and 36.5 
mmHg, respectively. On day 7, pO2 rose to 123 (high), and pCO2 fell to 29.2 (low). On day 9, the 
pO2 value remained as before, namely 123 mmHg (high), while pCO2 decreased to 23.1 mmHg 
(low). Furthermore, no follow-up was carried out for pO2 and pCO2. The chest X-ray on the second 
day of treatment showed pneumonia and cardiomegaly. On the 5th day, a chest CT scan was 
performed and showed bilateral pneumonia with ground-glass opacity. On the 7th day, the chest 
X-ray showed pneumonia results relatively the same as the 2nd-day photo. On the 10th day of 
examination, bilateral pneumonia improved from the 7th day. On the 15th day of examination, the 
results of bilateral pneumonia were relatively the same as the 10th day. Furthermore, on the last 
day of the treatment period (24th day), a chest CT scan was performed again, showing the results 
of bilateral pneumonia seen from ground-glass opacity in both lungs. Furthermore, for the RT-PCR 
results on the 2nd and 7th days, the RT-PCR results still showed positive results, and negative 
results were obtained on the 21st day of the treatment period. The patient received oxygenation 
therapy during the first day, nasal O2 at four lpm, and then from the second day to the tenth day. 
He received non-rebreathing mask oxygenation therapy of 8-10 lpm. KRS patient on the 24th day 
of treatment. 
In this study, therapeutic outcome parameters, inflammatory markers evaluated were 
CRP, d-dimer, IL-6, and/or fibrinogen as much as 100% (n=60) showed improved results. Still, in 
each patient, not all of these markers were monitored, or Follow-up was performed so that only 
one or two inflammatory markers could be shown before and after therapy. In the literature, it is 
stated that NAC is given until there is clinical improvement, improvement of chest x-ray, decrease 
in CRP (<10 mg/dL), or improvement of hyper inflammation (Suprabawati, 2020). NAC has a 
mechanism of action as a "glutathione-boosting treatment" that can increase the immune 
response and decrease pro-inflammatory cytokines to reduce the risk of the severity of COVID-19 
caused by cytokine storms in the body (Spearow, 2020). Glutathione is an antioxidant that plays a 
role in protecting cells from oxidative stress and is widely found in the body (Burhan et al., 2018). 
In addition, NAC inhibits lipopolysaccharide-mediated neurogenic inflammation by counteracting 
the release of Na, K-ATPase (NKA), a marker of cell necrosis, which may explain the decrease in IL-
6, as well as normalizing C-reactive protein (CRP) levels with the use of NAC  (Calzetta et al., 2018). 
The results of the RT-PCR test, which at the end of the treatment period still showed 
positive results (17.5%; n=10), this was because there were still virus fragments that were still 
detected by RT-PCR even though the virus was no longer active (Burhan et al., 2018). Chest X-rays 
as much as 69% (n=42) showed improved results from the previous results, and as many as 39% 
(n=14) gave relatively the same results as the first chest X-ray. Chest radiographs of patients 
showed 95% (n=57) had bilateral pneumonia and 3% (n=2) had bronchitis. 
Clinical data on oxygen saturation in patients with severe COVID-19 showed a saturation 
value of 95%. Still, only 37% (n=22) patients did not use oxygen on the day of KRS, while 63% (n=38 
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patients) received oxygen. The day of KRS is still assisted by oxygenation therapy which can be an 
O2 nasal, O2 simple mask, or O2 Non-rebreathing mask. Oxygen therapy is recommended by WHO 
and the Centers for Disease Control and Prevention (CDC) as first-line therapy to treat respiratory 
disorders and hypoxia due to COVID-19 with various administration methods determined by the 
severity of the disease (Whittle et al., 2020). Other clinical data, such as body temperature, blood 
pressure, cough, and pulse for all patients (n=60), showed improved results after treatment 
therapy. 
In addition to being an antioxidant, N-acetylcysteine (NAC) is a mucolytic agent that has a 
working mechanism, namely its free sulfhydryl (SH) group, which can reduce disulfide bonds, so it 
can be used to reduce the viscosity and elasticity of mucus (Santus et al., 2014). In this study, due 
to limited data in medical records, it was not possible to evaluate how NAC works as a mucolytic 
agent. Still, again it was only evaluated from other clinical data. 
The interaction between NAC and other drugs was not found or not written in the health 
medical record document, so a literature study carried out an analysis related to DRP (Drug 
Related Problem). NAC can interact with several metals such as iron (Fe) and copper (Cu), rubber, 
and oxygen and oxidizing compounds. Some antibiotics such as amphotericin B, ampicillin sodium, 
erythromycin lactobionate, and some tetracyclines are also physically incompatible with NAC or 
may become inactive (Sweetman, 2009). The NAC solution will change color and release hydrogen 
sulfide when iron, copper, rubber, and autoclaved. NAC does not react with plastic, glass, 
aluminum, silver, and stainless steel. The presence of light purple color in oral preparations and 
inhalation solutions also does not affect the drug's potency too much. Still, it is better to prevent it 
by using unreacted plastic and glass containers and using metal tools such as stainless steel when 
nebulized. The presence of a pink to light purple color in the injection preparation also does not 
affect the quality of the product (Mc Evoy, 2012). In COVID-19 patients, multivitamins and 
supplements were given, but from the results of this study, none of the multivitamins and 
supplements used contained iron (Fe), so no drug interactions occurred. 
Based on the description above, it can be seen that the use of high doses of NAC, namely 
[1 x 1200 - 5000 mg] po/iv in patients with severe COVID-19 at Bhayangkara Hospital Surabaya, 
resulted in improved conditions in patients without comorbidities with a length of treatment of 12 
days or with comorbid with 14 days of treatment. The length of treatment is influenced by NAC 
and is also influenced by the patient's condition and other drugs used. Data on therapeutic 
outcome parameters such as chest X-ray, inflammatory markers (CRP, d-dimer, IL-6) are not all 
followed up by hospitals, and this can be caused because COVID-19 is a complex disease, so that 
the parameters that determine the criteria for recovery patients viewed from many 
comprehensive aspects. 
 
CONCLUSION AND SUGGESTION 
Based on the study results of the Effectiveness of High-dose N-acetylcysteine in Patients 
with Severe COVID-19 at Bhayangkara H.S. Hospital. Samsoeri Mertojoso Surabaya in the period 
October 2020 to February 2021, it was concluded that the administration of N-Acetylcysteine 
(NAC) [1 x 1200 - 5000 mg] po/iv showed an improvement in condition in patients without 
comorbidities with a length of stay of 12 days or with comorbidities with a length of treatment 14 
days. In addition, the administration of NAC [1 x 1200 - 5000 mg] po/iv showed an improved 
clinical condition, free oxygen saturation >95% as much as 37%; 69% improvement in chest x-ray 
and improved inflammation, observed from CRP and d-dimer as much as 100%.  
The implication of research results on practice, administration of high dose N-
acetylcysteine can be considered because it provides evidence of clinical benefit for patients with 
Severe  COVID-19. 
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 Based on the limitations of this study, it is necessary to conduct further research on the 
effectiveness of high-dose NAC in patients with severe COVID-19, such as with prospective 
research methods and with the control group using certain dosage or control group without NAC 
therapy, to see the effectiveness of NAC more accurately.  
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